Medifocus Inc. announced that the company has entered into an agreement for the commercial development, and manufacturing of Medifocus' patented heat-activated and tumor targeted immuno-therapeutics with the Yuanxing Bio-Pharm Science &Technology Co. Ltd. Under the terms and conditions of the Agreement, Yuanxing will be responsible for development and manufacturing of commercial batches of the seed virus for Medifocus' heat activated immuno-therapeutics (CKA), which the company licensed from Duke University in October 2015, in sufficient quantities for pre-clinical evaluations in large animals as well as for the phase I clinical evaluation in patients. In addition, Yuanxing will advise and assist Medifocus in the regulatory process towards gaining CFDA approval for CKA and other heat activated genetic therapeutics in China.